Type 1 diabetes (T1D) is caused by autoimmune destruction of insulin-producing β cells
located in the endocrine pancreas in areas known as islets of Langerhans. The current …

Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …

Insulin degludec/insulin aspart (IDegAsp; 70% IDeg and 30% IAsp) is a soluble combination
of two individual insulin analogues in one product, designed to provide mealtime glycaemic …

Aim The aim of the present network meta-analysis is to assess the efficacy and safety across
different long and short-acting analogs for the treatment of type 2 diabetes. Methods A …

Insulin degludec/insulin aspart (IDegAsp) is a fixed-ratio co-formulation of insulin degludec
(IDeg), which provides long-lasting basal insulin coverage, and insulin aspart (IAsp), which …

Introduction Insulin degludec/insulin aspart (IDegAsp) is a fixed-ratio co-formulation of
insulin degludec (a basal insulin) and insulin aspart (a prandial insulin). The aim of this …

Diabetes is a chronic condition which affects the glucose metabolism in the body. In lieu of
any clinical “cure,” the condition is managed through the administration of pharmacological …

Aim To assess the efficacy and safety of iGlarLixi, a fixed‐ratio combination of basal insulin
glargine 100 U/mL and lixisenatide (glucagon‐like peptide‐1 receptor agonist) versus …

Insulin degludec/insulin aspart (IDegAsp) is a fixed‐ratio co‐formulation of insulin degludec,
which provides long‐lasting basal insulin coverage, and insulin aspart, which targets …

Introduction: Premix insulin is the most commonly used insulin preparation in India. The first
Indian premix guidelines were developed in 2009 and thereafter were updated in 2013 …